AR002958A1 - Derivados de acidos alcanoicos o fosfinicos que tienen un sustituyente triciclico, composiciones que los contienen y procedimiento para su preparacion - Google Patents
Derivados de acidos alcanoicos o fosfinicos que tienen un sustituyente triciclico, composiciones que los contienen y procedimiento para su preparacionInfo
- Publication number
- AR002958A1 AR002958A1 ARP960101275A AR10127596A AR002958A1 AR 002958 A1 AR002958 A1 AR 002958A1 AR P960101275 A ARP960101275 A AR P960101275A AR 10127596 A AR10127596 A AR 10127596A AR 002958 A1 AR002958 A1 AR 002958A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxycarbonyl
- hydrogen
- aralkoxycarbonyl
- naphth
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000002253 acid Substances 0.000 title 1
- 150000007513 acids Chemical class 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- -1 mercapto, acetylthio, carboxy, hydroxyaminocarbonyl Chemical group 0.000 abstract 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 abstract 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 abstract 1
- 108030004510 Interstitial collagenases Proteins 0.000 abstract 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 abstract 1
- 102000005741 Metalloproteases Human genes 0.000 abstract 1
- 108010006035 Metalloproteases Proteins 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 1
- 230000002917 arthritic effect Effects 0.000 abstract 1
- 125000001769 aryl amino group Chemical group 0.000 abstract 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 abstract 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 abstract 1
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 abstract 1
- 208000019664 bone resorption disease Diseases 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000005499 phosphonyl group Chemical group 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
Abstract
Compuestos de fórmula (I), como estereoisómero único o como mezcla de estereoisómeros, donde: m es 3,4,5 ó 6; y n es 0, 1, 3 ó 4; de modo que: cuandom es 3 ó 4; y n es 1, 2, 3 ó 4; entonces A es -CH2-, -O-, ó -N(R11)-, donde R11 eshidrógen o o alquilo; R1 es a) -CH2-R4 donde R4 es mercapto, acetiltio,carboxi, hidroxiaminocarbonilo, N-hidroxiformilamino, alcoxicarbonilo, ariloxicarbonilo, aralcoxicarbonilo, benciloxi-aminocarbonilo, ó -P(:O)OHS-R6en el cual R6 esquinol-2-ilo, naft-1-ilo, naft-2-ilo, piridilo o fenilo sustituido o no; b) -CH(R7)-R8 donde R8 es HOOC-, HOHNOC-; R7 es OH, NH2,alquilo, alquil o arilamino, alquilo, arilsulfonilamino, H2NOC-, alcoxi o aminocarbonilo, o -CH2NHR donde Res H, alquil- o aril-, 2-benzoxazol, -SO2Ra,-SO2NHRa, -SO2ORa, -C:ORa, -COORa, -CONHRa donde Ra es alquilo sustituido o no; ó c) -NH-CH(R9)-R10 donde R9 es hidrógeno, alquilo o aralquilo, y R10 escarboxi, alcoxicarbonilo o aralcoxicarbonilo,fosfonilo, dialquilfos fonilo o metoxifosfonilo; R2 es alquilo, trifluormetilalquilo, cicloalquilo,cicloalquilalquilo, arilo, ariloxialquilo o aralquilo; y R3 es hidrógeno, halo, alquilo o alcoxi; o cuando n es 0; y m es 4, 5 ó 6; entonces A es -CH(R12)donde R12 es carb oxi, alcoxicarbonilo u opcionalmente carbamoilo substituido. Son estereoisómeros únicos o mezclas de los mismos y sus salesfarmacéuticamente aceptables que inhiben las metaloproteasas de matriz, tales como colagenasasintersticiales y que son úti les para el tratamiento deenfermedades artríticas o enfermedades de resorción ósea, tales como osteoporosis.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/382,818 US6013792A (en) | 1993-08-05 | 1995-02-03 | Matrix metalloprotease inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR002958A1 true AR002958A1 (es) | 1998-05-27 |
Family
ID=23510527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP960101275A AR002958A1 (es) | 1995-02-03 | 1996-02-05 | Derivados de acidos alcanoicos o fosfinicos que tienen un sustituyente triciclico, composiciones que los contienen y procedimiento para su preparacion |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6013792A (es) |
| EP (1) | EP0807114A1 (es) |
| JP (1) | JPH11500109A (es) |
| KR (1) | KR100403687B1 (es) |
| CN (1) | CN1066150C (es) |
| AR (1) | AR002958A1 (es) |
| AU (1) | AU705763B2 (es) |
| BR (1) | BR9606998A (es) |
| CA (1) | CA2212236A1 (es) |
| CZ (1) | CZ293868B6 (es) |
| FI (1) | FI113965B (es) |
| HU (1) | HUP9702073A3 (es) |
| NO (1) | NO311257B1 (es) |
| PL (1) | PL321659A1 (es) |
| RU (1) | RU2191779C2 (es) |
| UA (1) | UA67716C2 (es) |
| WO (1) | WO1996023791A1 (es) |
| ZA (1) | ZA96850B (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR19990072009A (ko) * | 1995-08-12 | 1999-09-27 | 게리 이. 프리드만 | 메탈로프로티나제 방해제, 그를 포함하는 약제 조성물 및 약제로서의 용도, 그리고 그의 제조방법 및 제조에 유용한 중간체 |
| US6500948B1 (en) | 1995-12-08 | 2002-12-31 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof |
| US6174915B1 (en) | 1997-03-25 | 2001-01-16 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
| US6008243A (en) * | 1996-10-24 | 1999-12-28 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use |
| US5985900A (en) * | 1997-04-01 | 1999-11-16 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
| GB9715030D0 (en) | 1997-07-18 | 1997-09-24 | British Biotech Pharm | Metalloproteinase inhibitors |
| US6858598B1 (en) | 1998-12-23 | 2005-02-22 | G. D. Searle & Co. | Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| GB9907055D0 (en) * | 1999-03-29 | 1999-05-19 | British Biotech Pharm | Antibacterial agents |
| AR032920A1 (es) * | 2001-03-01 | 2003-12-03 | Smithkline Beecham Corp | Compuestos inhibidores de las peptido-deformilasas y medios para tratar infecciones bacterianas utilizando dichos inhibidores |
| UY27813A1 (es) * | 2002-05-31 | 2003-12-31 | Smithkline Beecham Corp | Inhibidores de la peptido-desformilasa |
| BR0317715A (pt) * | 2002-12-27 | 2005-11-22 | Angiotech Int Ag | Composições e processos de uso de collajolie |
| JP2006516548A (ja) | 2002-12-30 | 2006-07-06 | アンジオテック インターナショナル アクツィエン ゲゼルシャフト | 迅速ゲル化ポリマー組成物からの薬物送達法 |
| US7927579B2 (en) * | 2003-01-17 | 2011-04-19 | Advanced Proteome Therapeutics, Inc | Tandem analyses of noncovalently driven effectors for modulatory mapping of activities of protein sites |
| AU2003902115A0 (en) * | 2003-05-02 | 2003-05-22 | The University Of Queensland | Method of predicting functional outcome of a stroke using eeg measures |
| RU2247563C1 (ru) * | 2003-06-16 | 2005-03-10 | Пятигорская государственная фармацевтическая академия | Способ получения твердой лекарственной формы, содержащей глюкозамина гидрохлорид |
| CA2533820C (en) * | 2003-07-31 | 2016-12-13 | Tranzyme Pharma | Spatially-defined macrocycles incorporating peptide bond surrogates |
| RU2257386C1 (ru) * | 2004-05-05 | 2005-07-27 | Пермский государственный университет | 20-ароил-12-гидрокси-17,17-диметил-3-фенил-3,10,13- триазапентацикло[10.7.1.01,10.04,9.014,19]эйкоза-4,6,8,14(19)-тетраен- 2,11,15- трионы и способ их получения |
| KR100753796B1 (ko) | 2006-07-28 | 2007-08-31 | 주식회사 프로메디텍 | 데포르밀라제 저해제, 이의 제조방법, 및 이를 포함하는조성물 |
| UA108596C2 (xx) * | 2007-11-09 | 2015-05-25 | Інгібітори пептиддеформілази | |
| CN105801530A (zh) * | 2016-04-13 | 2016-07-27 | 成都拿盛科技有限公司 | 一种4位取代的手性γ-丁内酯的合成方法 |
| KR20220105061A (ko) | 2021-01-19 | 2022-07-26 | (주)월드트렌드 | 밀착력과 착용감 향상 및 수시 교체가 가능한 안경테와 코 받침의 조립구조 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4761406A (en) * | 1985-06-06 | 1988-08-02 | The Procter & Gamble Company | Regimen for treating osteoporosis |
| GB9000846D0 (en) * | 1990-01-15 | 1990-03-14 | Beecham Group Plc | Novel compounds |
| GB9022117D0 (en) * | 1990-10-11 | 1990-11-21 | Beecham Group Plc | Novel compounds |
| US5189178A (en) * | 1990-11-21 | 1993-02-23 | Galardy Richard E | Matrix metalloprotease inhibitors |
| US5183900A (en) * | 1990-11-21 | 1993-02-02 | Galardy Richard E | Matrix metalloprotease inhibitors |
| WO1992021360A1 (en) * | 1991-05-28 | 1992-12-10 | Merck & Co., Inc. | Substituted n-carboxyalkylpeptidyl derivatives as antidegenerative active agents |
| GB9122859D0 (en) * | 1991-10-28 | 1991-12-11 | Smithkline Beecham Plc | Novel compounds |
| NZ246456A (en) * | 1991-12-17 | 1997-03-24 | Procter & Gamble Pharma | Use of bone active phosphonate and a parathyroid hormone to prepare medicaments for a thirty day treatment regimen for osteoporosis |
| DK0712403T3 (da) * | 1993-08-05 | 1998-01-26 | Syntex Inc | Matrix-metalloproteaseinhibitorer |
-
1995
- 1995-02-03 US US08/382,818 patent/US6013792A/en not_active Expired - Fee Related
-
1996
- 1996-02-02 KR KR1019970705256A patent/KR100403687B1/ko not_active Expired - Fee Related
- 1996-02-02 UA UA97094471A patent/UA67716C2/uk unknown
- 1996-02-02 JP JP8523770A patent/JPH11500109A/ja not_active Ceased
- 1996-02-02 PL PL96321659A patent/PL321659A1/xx unknown
- 1996-02-02 HU HU9702073A patent/HUP9702073A3/hu unknown
- 1996-02-02 WO PCT/US1996/001506 patent/WO1996023791A1/en not_active Ceased
- 1996-02-02 CA CA002212236A patent/CA2212236A1/en not_active Abandoned
- 1996-02-02 RU RU97115238/04A patent/RU2191779C2/ru not_active IP Right Cessation
- 1996-02-02 EP EP96904563A patent/EP0807114A1/en not_active Withdrawn
- 1996-02-02 CN CN96192984A patent/CN1066150C/zh not_active Expired - Fee Related
- 1996-02-02 AU AU48636/96A patent/AU705763B2/en not_active Ceased
- 1996-02-02 CZ CZ19972431A patent/CZ293868B6/cs not_active IP Right Cessation
- 1996-02-02 ZA ZA9600850A patent/ZA96850B/xx unknown
- 1996-02-02 BR BR9606998A patent/BR9606998A/pt not_active Application Discontinuation
- 1996-02-05 AR ARP960101275A patent/AR002958A1/es not_active Application Discontinuation
-
1997
- 1997-08-01 FI FI973198A patent/FI113965B/fi not_active IP Right Cessation
- 1997-08-01 NO NO19973551A patent/NO311257B1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO973551D0 (no) | 1997-08-01 |
| PL321659A1 (en) | 1997-12-22 |
| WO1996023791A1 (en) | 1996-08-08 |
| NO973551L (no) | 1997-10-03 |
| KR100403687B1 (ko) | 2004-02-11 |
| AU705763B2 (en) | 1999-06-03 |
| AU4863696A (en) | 1996-08-21 |
| CN1066150C (zh) | 2001-05-23 |
| BR9606998A (pt) | 1997-10-28 |
| JPH11500109A (ja) | 1999-01-06 |
| HUP9702073A2 (hu) | 1998-03-30 |
| FI113965B (fi) | 2004-07-15 |
| NO311257B1 (no) | 2001-11-05 |
| CA2212236A1 (en) | 1996-08-08 |
| HUP9702073A3 (en) | 1999-05-28 |
| CN1180358A (zh) | 1998-04-29 |
| RU2191779C2 (ru) | 2002-10-27 |
| FI973198A0 (fi) | 1997-08-01 |
| EP0807114A1 (en) | 1997-11-19 |
| CZ293868B6 (cs) | 2004-08-18 |
| US6013792A (en) | 2000-01-11 |
| UA67716C2 (en) | 2004-07-15 |
| CZ243197A3 (cs) | 1998-01-14 |
| ZA96850B (en) | 1997-11-03 |
| FI973198L (fi) | 1997-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR002958A1 (es) | Derivados de acidos alcanoicos o fosfinicos que tienen un sustituyente triciclico, composiciones que los contienen y procedimiento para su preparacion | |
| ES2105744T3 (es) | Inhibidores de metaloproteasas matriciales. | |
| ATE557002T1 (de) | Verbindungen mit calcimimetischer wirkung | |
| FI3880197T3 (fi) | Menetelmiä kystisen fibroosin hoitamiseksi | |
| AR046964A1 (es) | Heterociclos azabiciclicos como moduladores de receptor canabinoide, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades relacionadas con trastornos metabolicos y de la alimentacion. | |
| AR016548A1 (es) | Compuestos de analogos de nucleotidos, un metodo para su preparacion, una composicion que los comprende, un producto producido mediante el proceso de comprimir una mezcla y un metodo para preparar 9-[2-(dietilfosfonometoxi)etil]adenina. | |
| DK0623347T3 (da) | Anvendelse af bisphosphonsyrederivater til fremstilling af et lægemiddel til fremme af knogleheling | |
| US4230700A (en) | Methods for inhibiting mobilization of calcium phosphate in animal tissue | |
| DK0683789T3 (da) | N-alkyl-2-substituerede ATP-analoger | |
| BR0210504A (pt) | Derivados de naftil-indol substituidos, atuantes como inibidores do inibidor tipo 1 (pai-1) do ativador de plasminogênio | |
| US4330537A (en) | Compositions for inhibiting mobilization of calcium phosphate in animal tissue | |
| JP2005511748A (ja) | Ｔ−ガンマ−９−デルタ−２リンパ球の活性のモジュレーターとして有用なホスホネート | |
| CA2024694C (en) | Acyloxymethyl esters of bisphosphonic acids as bone resorption inhibitors | |
| ES2149403T3 (es) | Benciloxicarbonilguanidinas sustituidas como inhibidores del intercambiador de protones de sodio, procedimiento para su preparacion, su empleo como medicamento o agente de diagnostico, asi como medicamento que las contiene. | |
| MX9303243A (es) | Compuestos de fosfonato novedosos que contienen nitrogeno cuaternario, composiciones farmaceuticas y metodos para tratar el metabolismo anormal del calcio y el fosfato, y metodos para tratar y prevenir calculos dentales y placa dental. | |
| AR016448A1 (es) | Bifenilsulfonilcianamidas y preparacion farmaceutica que las contiene. | |
| NO924991D0 (no) | Nye 2-sakkarinylmetyl- og 4,5,6,7-tetrahydro-2-sakkarinyl-metylfosfater, -fosfonater og -fosfinater som er nyttige som inhibitorer for proteolytiske enzymer, samt preparaterog fremgangsmaate for anvendelse derav | |
| EA200000374A2 (ru) | Новые соединения 2,3-метаноаминокислоты, способ их получения и содержащие их фармацевтические композиции | |
| NO960250L (no) | Nye mercaptoalkanoyldipeptidforbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdende dem | |
| FI950259A0 (fi) | Uudet, asykliset, amidiiniryhmiä sisältävät difosfonihappojohdannaiset, menetelmä niiden valmistamiseksi ja näitä yhdisteitä sisältävät lääkeaineet | |
| HUP0103327A2 (hu) | Trombózis-ellenes hatású szubsztituált fenil-amidinek | |
| KR890006233A (ko) | 인-함유 2-이속사졸린 및 이속사졸, 이를 함유하는 약학제제 및 이들 헤테로 사이클릭 화합물의 제조 방법 | |
| Henk et al. | Clinical findings and main considerations of the use of bisphosphonate in dental implants: a concise systematic review | |
| MX9301155A (es) | Nuevas sulfonamidocarboxamidas y procedimiento para su preparacion. | |
| AR013500A1 (es) | Uso de acido alendronico o una sal farmaceuticamente aceptable del mismo o una mezcal de los mismos para la manufactura de un medicamento |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |